+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, and Assays), By Application, By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others), By Regional Outlook and Forecast, 2024 - 2031

  • PDF Icon

    Report

  • May 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5976249
The Global PARP Inhibitor Biomarkers Market size is expected to reach $1.6 billion by 2031, rising at a market growth of 8.3% CAGR during the forecast period.

North America boasts advanced healthcare infrastructure, including well-established clinical laboratories, oncology centres, and research institutions. Thus, the North America region acquired 42.5% revenue share in the market 2023. The availability of diagnostic technologies and skilled healthcare professionals enhances the accessibility and utilization of biomarker testing services, driving the demand for it in North America.



Oncology research is continually uncovering new biomarkers associated with cancer development, progression, and response to therapy. As our understanding of the molecular pathways underlying cancer improves, researchers are identifying biomarkers that predict response to specific treatments, including it.

Additionally, point-of-care testing brings diagnostic capabilities closer to the patient, enabling biomarker testing to be performed outside traditional laboratory settings, such as outpatient clinics, physician offices, or even the patient’s home. Hence, the expansion of point-of-care testing is raising the market’s growth.

However, Biomarker testing often involves sophisticated laboratory techniques and specialized equipment, which can be expensive to procure and maintain. Additionally, the cost of reagents, consumables, and personnel required for biomarker testing adds to the overall expense. In conclusion, the high cost of biomarker testing hinders the market’s growth.

Economic hardships and changes in healthcare priorities during the pandemic affected patient access to cancer treatments, including this. Financial constraints, job losses, and changes in insurance coverage may have influenced treatment decisions and patient adherence. Thus, the COVID-19 pandemic had a negative impact on the market.

Driving and Restraining Factors

Drivers
  • Growing expansion of oncology research
  • Expansion of point-of-care testing
  • Increasing prevalence of cancer worldwide
Restraints
  • High cost of biomarker testing
  • Complexity of biomarker interpretation
Opportunities
  • Growing awareness of biomarker testing
  • Increasing development healthcare infrastructure
Challenges
  • Limited availability of targeted therapies
  • Increasing competition from alternative therapies

Product Outlook

Based on product, the market is divided into kits and assays. In 2023, the kits segment garnered 63.8% revenue share in the market. Biomarker testing kits offer a user-friendly and convenient solution for healthcare providers to perform biomarker testing in-house without requiring specialized laboratory infrastructure or expertise.

Application Outlook

Based on application, the market is categorized into breast cancer, ovarian cancer, and others. The ovarian cancer segment witnessed 30.7% revenue share in the market in 2023. PARP inhibitors have demonstrated clinical efficacy in treating ovarian cancer patients with BRCA mutations. Clinical trials have shown that PARP inhibitors.



Services Outlook

On the basis of services, the market is segmented into BRCA 1 & 2 testing, HRD testing, HRR testing, and others. The BRCA 1 & 2 testing segment recorded 41.8% revenue share in the market in 2023. BRCA1 and BRCA2 mutations are strongly associated with increased sensitivity to this in certain cancers, particularly breast and ovarian cancer.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated 24.4% revenue share in the market. The Asia Pacific region is experiencing a significant increase in the incidence of cancer, including breast, ovarian, and other cancers associated with PARP inhibitor therapy.

List of Key Companies Profiled

  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline PLC (GSK)

Market Report Segmentation

By Product
  • Kits
  • Assays
By Application
  • Breast Cancer
  • Ovarian Cancer
  • Others
By Services
  • BRCA 1 & 2 Testing
  • HRD Testing
  • HRR Testing
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global PARP Inhibitor Biomarkers Market, by Product
1.4.2 Global PARP Inhibitor Biomarkers Market, by Application
1.4.3 Global PARP Inhibitor Biomarkers Market, by Services
1.4.4 Global PARP Inhibitor Biomarkers Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Global PARP Inhibitor Biomarkers Market by Product
4.1 Global Kits Market by Region
4.2 Global Assays Market by Region
Chapter 5. Global PARP Inhibitor Biomarkers Market by Application
5.1 Global Breast Cancer Market by Region
5.2 Global Ovarian Cancer Market by Region
5.3 Global Others Market by Region
Chapter 6. Global PARP Inhibitor Biomarkers Market by Services
6.1 Global BRCA 1 & 2 Testing Market by Region
6.2 Global HRD Testing Market by Region
6.3 Global HRR Testing Market by Region
6.4 Global Others Market by Region
Chapter 7. Global PARP Inhibitor Biomarkers Market by Region
7.1 North America PARP Inhibitor Biomarkers Market
7.1.1 North America PARP Inhibitor Biomarkers Market by Product
7.1.1.1 North America Kits Market by Region
7.1.1.2 North America Assays Market by Region
7.1.2 North America PARP Inhibitor Biomarkers Market by Application
7.1.2.1 North America Breast Cancer Market by Country
7.1.2.2 North America Ovarian Cancer Market by Country
7.1.2.3 North America Others Market by Country
7.1.3 North America PARP Inhibitor Biomarkers Market by Services
7.1.3.1 North America BRCA 1 & 2 Testing Market by Country
7.1.3.2 North America HRD Testing Market by Country
7.1.3.3 North America HRR Testing Market by Country
7.1.3.4 North America Others Market by Country
7.1.4 North America PARP Inhibitor Biomarkers Market by Country
7.1.4.1 US PARP Inhibitor Biomarkers Market
7.1.4.1.1 US PARP Inhibitor Biomarkers Market by Product
7.1.4.1.2 US PARP Inhibitor Biomarkers Market by Application
7.1.4.1.3 US PARP Inhibitor Biomarkers Market by Services
7.1.4.2 Canada PARP Inhibitor Biomarkers Market
7.1.4.2.1 Canada PARP Inhibitor Biomarkers Market by Product
7.1.4.2.2 Canada PARP Inhibitor Biomarkers Market by Application
7.1.4.2.3 Canada PARP Inhibitor Biomarkers Market by Services
7.1.4.3 Mexico PARP Inhibitor Biomarkers Market
7.1.4.3.1 Mexico PARP Inhibitor Biomarkers Market by Product
7.1.4.3.2 Mexico PARP Inhibitor Biomarkers Market by Application
7.1.4.3.3 Mexico PARP Inhibitor Biomarkers Market by Services
7.1.4.4 Rest of North America PARP Inhibitor Biomarkers Market
7.1.4.4.1 Rest of North America PARP Inhibitor Biomarkers Market by Product
7.1.4.4.2 Rest of North America PARP Inhibitor Biomarkers Market by Application
7.1.4.4.3 Rest of North America PARP Inhibitor Biomarkers Market by Services
7.2 Europe PARP Inhibitor Biomarkers Market
7.2.1 Europe PARP Inhibitor Biomarkers Market by Product
7.2.1.1 Europe Kits Market by Country
7.2.1.2 Europe Assays Market by Country
7.2.2 Europe PARP Inhibitor Biomarkers Market by Application
7.2.2.1 Europe Breast Cancer Market by Country
7.2.2.2 Europe Ovarian Cancer Market by Country
7.2.2.3 Europe Others Market by Country
7.2.3 Europe PARP Inhibitor Biomarkers Market by Services
7.2.3.1 Europe BRCA 1 & 2 Testing Market by Country
7.2.3.2 Europe HRD Testing Market by Country
7.2.3.3 Europe HRR Testing Market by Country
7.2.3.4 Europe Others Market by Country
7.2.4 Europe PARP Inhibitor Biomarkers Market by Country
7.2.4.1 Germany PARP Inhibitor Biomarkers Market
7.2.4.1.1 Germany PARP Inhibitor Biomarkers Market by Product
7.2.4.1.2 Germany PARP Inhibitor Biomarkers Market by Application
7.2.4.1.3 Germany PARP Inhibitor Biomarkers Market by Services
7.2.4.2 UK PARP Inhibitor Biomarkers Market
7.2.4.2.1 UK PARP Inhibitor Biomarkers Market by Product
7.2.4.2.2 UK PARP Inhibitor Biomarkers Market by Application
7.2.4.2.3 UK PARP Inhibitor Biomarkers Market by Services
7.2.4.3 France PARP Inhibitor Biomarkers Market
7.2.4.3.1 France PARP Inhibitor Biomarkers Market by Product
7.2.4.3.2 France PARP Inhibitor Biomarkers Market by Application
7.2.4.3.3 France PARP Inhibitor Biomarkers Market by Services
7.2.4.4 Russia PARP Inhibitor Biomarkers Market
7.2.4.4.1 Russia PARP Inhibitor Biomarkers Market by Product
7.2.4.4.2 Russia PARP Inhibitor Biomarkers Market by Application
7.2.4.4.3 Russia PARP Inhibitor Biomarkers Market by Services
7.2.4.5 Spain PARP Inhibitor Biomarkers Market
7.2.4.5.1 Spain PARP Inhibitor Biomarkers Market by Product
7.2.4.5.2 Spain PARP Inhibitor Biomarkers Market by Application
7.2.4.5.3 Spain PARP Inhibitor Biomarkers Market by Services
7.2.4.6 Italy PARP Inhibitor Biomarkers Market
7.2.4.6.1 Italy PARP Inhibitor Biomarkers Market by Product
7.2.4.6.2 Italy PARP Inhibitor Biomarkers Market by Application
7.2.4.6.3 Italy PARP Inhibitor Biomarkers Market by Services
7.2.4.7 Rest of Europe PARP Inhibitor Biomarkers Market
7.2.4.7.1 Rest of Europe PARP Inhibitor Biomarkers Market by Product
7.2.4.7.2 Rest of Europe PARP Inhibitor Biomarkers Market by Application
7.2.4.7.3 Rest of Europe PARP Inhibitor Biomarkers Market by Services
7.3 Asia Pacific PARP Inhibitor Biomarkers Market
7.3.1 Asia Pacific PARP Inhibitor Biomarkers Market by Product
7.3.1.1 Asia Pacific Kits Market by Country
7.3.1.2 Asia Pacific Assays Market by Country
7.3.2 Asia Pacific PARP Inhibitor Biomarkers Market by Application
7.3.2.1 Asia Pacific Breast Cancer Market by Country
7.3.2.2 Asia Pacific Ovarian Cancer Market by Country
7.3.2.3 Asia Pacific Others Market by Country
7.3.3 Asia Pacific PARP Inhibitor Biomarkers Market by Services
7.3.3.1 Asia Pacific BRCA 1 & 2 Testing Market by Country
7.3.3.2 Asia Pacific HRD Testing Market by Country
7.3.3.3 Asia Pacific HRR Testing Market by Country
7.3.3.4 Asia Pacific Others Market by Country
7.3.4 Asia Pacific PARP Inhibitor Biomarkers Market by Country
7.3.4.1 China PARP Inhibitor Biomarkers Market
7.3.4.1.1 China PARP Inhibitor Biomarkers Market by Product
7.3.4.1.2 China PARP Inhibitor Biomarkers Market by Application
7.3.4.1.3 China PARP Inhibitor Biomarkers Market by Services
7.3.4.2 Japan PARP Inhibitor Biomarkers Market
7.3.4.2.1 Japan PARP Inhibitor Biomarkers Market by Product
7.3.4.2.2 Japan PARP Inhibitor Biomarkers Market by Application
7.3.4.2.3 Japan PARP Inhibitor Biomarkers Market by Services
7.3.4.3 India PARP Inhibitor Biomarkers Market
7.3.4.3.1 India PARP Inhibitor Biomarkers Market by Product
7.3.4.3.2 India PARP Inhibitor Biomarkers Market by Application
7.3.4.3.3 India PARP Inhibitor Biomarkers Market by Services
7.3.4.4 South Korea PARP Inhibitor Biomarkers Market
7.3.4.4.1 South Korea PARP Inhibitor Biomarkers Market by Product
7.3.4.4.2 South Korea PARP Inhibitor Biomarkers Market by Application
7.3.4.4.3 South Korea PARP Inhibitor Biomarkers Market by Services
7.3.4.5 Singapore PARP Inhibitor Biomarkers Market
7.3.4.5.1 Singapore PARP Inhibitor Biomarkers Market by Product
7.3.4.5.2 Singapore PARP Inhibitor Biomarkers Market by Application
7.3.4.5.3 Singapore PARP Inhibitor Biomarkers Market by Services
7.3.4.6 Malaysia PARP Inhibitor Biomarkers Market
7.3.4.6.1 Malaysia PARP Inhibitor Biomarkers Market by Product
7.3.4.6.2 Malaysia PARP Inhibitor Biomarkers Market by Application
7.3.4.6.3 Malaysia PARP Inhibitor Biomarkers Market by Services
7.3.4.7 Rest of Asia Pacific PARP Inhibitor Biomarkers Market
7.3.4.7.1 Rest of Asia Pacific PARP Inhibitor Biomarkers Market by Product
7.3.4.7.2 Rest of Asia Pacific PARP Inhibitor Biomarkers Market by Application
7.3.4.7.3 Rest of Asia Pacific PARP Inhibitor Biomarkers Market by Services
7.4 LAMEA PARP Inhibitor Biomarkers Market
7.4.1 LAMEA PARP Inhibitor Biomarkers Market by Product
7.4.1.1 LAMEA Kits Market by Country
7.4.1.2 LAMEA Assays Market by Country
7.4.2 LAMEA PARP Inhibitor Biomarkers Market by Application
7.4.2.1 LAMEA Breast Cancer Market by Country
7.4.2.2 LAMEA Ovarian Cancer Market by Country
7.4.2.3 LAMEA Others Market by Country
7.4.3 LAMEA PARP Inhibitor Biomarkers Market by Services
7.4.3.1 LAMEA BRCA 1 & 2 Testing Market by Country
7.4.3.2 LAMEA HRD Testing Market by Country
7.4.3.3 LAMEA HRR Testing Market by Country
7.4.3.4 LAMEA Others Market by Country
7.4.4 LAMEA PARP Inhibitor Biomarkers Market by Country
7.4.4.1 Brazil PARP Inhibitor Biomarkers Market
7.4.4.1.1 Brazil PARP Inhibitor Biomarkers Market by Product
7.4.4.1.2 Brazil PARP Inhibitor Biomarkers Market by Application
7.4.4.1.3 Brazil PARP Inhibitor Biomarkers Market by Services
7.4.4.2 Argentina PARP Inhibitor Biomarkers Market
7.4.4.2.1 Argentina PARP Inhibitor Biomarkers Market by Product
7.4.4.2.2 Argentina PARP Inhibitor Biomarkers Market by Application
7.4.4.2.3 Argentina PARP Inhibitor Biomarkers Market by Services
7.4.4.3 UAE PARP Inhibitor Biomarkers Market
7.4.4.3.1 UAE PARP Inhibitor Biomarkers Market by Product
7.4.4.3.2 UAE PARP Inhibitor Biomarkers Market by Application
7.4.4.3.3 UAE PARP Inhibitor Biomarkers Market by Services
7.4.4.4 Saudi Arabia PARP Inhibitor Biomarkers Market
7.4.4.4.1 Saudi Arabia PARP Inhibitor Biomarkers Market by Product
7.4.4.4.2 Saudi Arabia PARP Inhibitor Biomarkers Market by Application
7.4.4.4.3 Saudi Arabia PARP Inhibitor Biomarkers Market by Services
7.4.4.5 South Africa PARP Inhibitor Biomarkers Market
7.4.4.5.1 South Africa PARP Inhibitor Biomarkers Market by Product
7.4.4.5.2 South Africa PARP Inhibitor Biomarkers Market by Application
7.4.4.5.3 South Africa PARP Inhibitor Biomarkers Market by Services
7.4.4.6 Nigeria PARP Inhibitor Biomarkers Market
7.4.4.6.1 Nigeria PARP Inhibitor Biomarkers Market by Product
7.4.4.6.2 Nigeria PARP Inhibitor Biomarkers Market by Application
7.4.4.6.3 Nigeria PARP Inhibitor Biomarkers Market by Services
7.4.4.7 Rest of LAMEA PARP Inhibitor Biomarkers Market
7.4.4.7.1 Rest of LAMEA PARP Inhibitor Biomarkers Market by Product
7.4.4.7.2 Rest of LAMEA PARP Inhibitor Biomarkers Market by Application
7.4.4.7.3 Rest of LAMEA PARP Inhibitor Biomarkers Market by Services
Chapter 8. Company Profiles
8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 SWOT Analysis
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Neogenomics, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Qiagen N.V.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Agilent Technologies, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Merck KGaA
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 AstraZeneca PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis
Chapter 9. Winning Imperatives of PARP Inhibitor Biomarkers Market

Companies Mentioned

  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Bayer AG
  • AstraZeneca PLC
  • GlaxoSmithKline PLC (GSK)

Methodology

Loading
LOADING...